How Hims & Hers Reached a $4.3BN Market Cap on $2.3BN of Revenue | Andrew Dudum

HIMS CEO Andrew Dudham discusses the company's strategy of utilizing public market pressures to accelerate innovation across ten clinical categories, achieving $2.3 billion in annual revenue despite a recent 66% stock decline. By deploying AI to enhance operational efficiency and leveraging a diversified portfolio to disrupt pricing models like those for GLP-1 treatments, the firm aims to standardize care while funding international expansion through the acquisition of Eucalyptus. The organization prioritizes physical fulfillment infrastructure and patient outcome alignment over speed, hiring high-grit talent to execute a long-term vision of making advanced healthcare accessible at significantly lower costs.